European Journal of Molecular & Clinical Medicine

ISSN 2515-8260 Volume 07, Issue 07, 2020

A REVIEW ON USE OF TOCILIZUMAB FOR THE TREATMENT OF COVID-19

Dr.Elayakumar S.T Senior Resident[1],

Dr. Anbumalar M Assistant Professor[2]

Meenakshi Academy of Higher Education and Research

anbumalar@mmchri.ac.in

Abstract

Although a viral infection begins in COVID-19, some patients have overly exuberant inflammation, leading to acute pulmonary injury and a condition of adult respiratory distress (ARDS). As IL-6 is a key role in the inflammatory response, in this single centre observatory study in all Covid-19 patients with a proven SARS-CoV-2 fast-pacing infection in order to escape ALI and ARDS we have assessed the effectiveness and protection of tocilizumab (TCZ). In this single centre The rate of mortality in 104 patients treated for COVID-19 was lower (5 · 8%). The percentage of patients treated with COVID-19 was 11% lower than in untreated patients who had our level of treatment alone and a marginally lower rate of mortality (6 percent). The acute phase reagents, Ferritin, and liver protein releases were quickly diminished by TCZ. Slowly, D-Dimer declined. Relevant safety issues were not found. An early prescribing of IL6-R antagonists can be safe and successful for avoidance, ICU admission and more complications in COVID-19 patients with imminent hyperinflammatory reaction[1].

Keywords: COVID-19, Tocilizumab, Pandemic, Treatment

BACKGROUND

The evidence indicates that the immediate and rapid release of various cytokines as a serious immune reaction ("cytokine release syndrome" CRS) is present in sub-sets of extreme COVID-19 patients, contributing to acute respirory distress syndrome (ARDS). This septic storm will lead to life-threatening failure of a variety of organs. The CRS may be induced by infections, trauma, or clinical intervention such as a chimeric antigen receptor (CAR)-T cell injection, first described in previous outbreak procedures in patients with severe acute respiratory Syndrome (SARS) or Middle East Respiratory syndrome (MERS-CoV), all caused by corónaviruses. Immune response dysregulation was also recorded in COVID-19[2–5]. Interestingly, the extensive cytokine storm is played by IL-2, IL- 7, IL-10, IL-12, interferon β, inflammatory macrophage protein 1-α, and tumour necrosis factor-α, while the excellent cytokine seems to have IL-6. IL-6 is a pleiotropically activated cytokine. The defensive work against the viruses repairing the tissue affected by this acute process and by immune responses is carried out by mainly macrophages, fibroblasts and dendritic cells in response to pathogen allocated molecular patterns (PAMPs) or molecular damage-associated patterns (DAMPs). In most extreme COVID-19 cases the existence of CRS has been showed to be a stimulating factor in granulocytes-colony-colony (G-CSF), interferon-α-inducible protein

ISSN 2515-8260 Volume 07, Issue 07, 2020

(IP10), monocyte chemoattractant protein (MCP1), macro-colonial inflammatory protein 1 alpha (MIP1A). In the end, IL-6 will reach vast amounts of inflammatory cytokines, causing physical lung disability and death[6–8].

The recombinant humanised anti-interleukin-6 (IL-6R) monoclonal antibody, Tocilizumab (TCZ), has been found to be an alternative for use in this outbreak that prevents IL-6 from binding to solutionble and membrane-bound IL-6R Based on methodologically weak, but positive results of tocilizumab in the treatment of severe COVID-19 patients from observational studies, case reports [9–11] and the experience of tocilizumab in inducing rapid reversal of CAR T cell-induced CRS , several clinical trials are being conducted to assess the efficacy and safety of tocilizumab in severe COVID-19 patients.

Tocilizumab for the treatment of COVID-19

The current COVID19 pandemic is a challenge to world health and health services that is unparalleled. Older individuals with age-related illnesses that experience hyper-inflammatory syndrome are the highest mortality rate. Here, we believed that the magnitude of COVID-19 may be associated with inflammation. Here the clinical response assessments for a one dose intravenous injection of the anti-IL-6 receptor Tocilizumab (TCZ) in COVID-19 patients [12–15]with multifocal interstitial pneumonia were evaluated by 30 serum samples from patients registered in the Clinical trial NCT04315480.We have assessed a range of RNAs that regulate inflammatory activity (i.e. miR-146a-5p, miR-21-5, and miR-126-3p) quantified by RT-PCR and Droplet Digital PCR, in these serum samples as well as in 29 age- and gender-based stable control subjects. Signified dysregulation by pro-inflammatory cytokines, a syndrome termed cytokine storm, is present in a large proportion of hospitalised COVID-19 patients[16–18]. In COVID-19 patients, such hyperinflammatory reaction is consistent with severe pneumonia and endothelial injury and microvascular dysfunction as well as with the lung and multiorgan insufficiency. Consequently, the efficacy of anticytokine/cytokine receptor antibodies for the treatment of COVID 19 patients is unsurprising to have been started in a series of clinical studies One of such host-directed therapies is tocilizumab (TCZ), the monoclonal interleukin-6 (IL-6) receptor antibody. However a major heterogeneity has been documented in the clinical response of COVID-19 patients to TCZ therapy, possibly because of the contribution of other considerations like age-related biological processes, gender, genetic composition, seriousness of the disorder, timing, and immune activation. On the above issue, recently we have indicated that unregulated COVID-19 associated hyperinflammation can be promoted by age based pro-inflammatory status that is currently referred to as inflammatory, particularly in ages. It is desperately important to channel this useful armament to those patients that are more likely to gain from blood bio-markers that are conceivablely related to systemic inflammatory disorders and/or inflammation and are capable of predirecting the reaction to TCZ therapy. From this point of view, the evaluation of microRNAs (miRNAs), including age associated and infectious diseases, has emerged like a reliable instrument to determine the pharmacologic therapies in a range of human diseases. Many recent research showed that a major cause of death in COVID-19 patients was the Cytokine Freedom syndrome (CRS), of which IL-6 was an important component. Herold et al. found the IL-6 level in patients with COVID-19 to predict respiratory failure (including 40 patients). The rise in IL-6 has been closely associated with mechanical ventilation criteria (p

ISSN 2515-8260 Volume 07, Issue 07, 2020

< 0.001). Furthermore, patients with highest IL-6 could easily predict respiratory insufficiency (p<0,001, AUC=0,98). A 92% chance of respiratory failure was present for patients with IL-6 levels < 80 pg/mL, twenty-two times higher than for those with low IL-6. [19–22] have also demonstrated a strong link between the rise in the level of IL-6 and the severity of COVID-19. The IL-6 has reduced dramatically and the pulmonary imaging test in 25 cases has been increased. Around the same time, 3 patients' IL-6 level rose further and the condition declined.

DISCUSSION

Tocilizumab was an interleukin 6(IL-6) human receptor recombinant humanised, monoclonal antibody. It is primarily used for treating rheumatoid arthritis and chronic idiopathic arthritis in young children. Furthermore, some reports successfully apply for CRS therapy indicate that overactivated immune responses triggered by the pathogenic cells GM-CSF+T1 and inflammatory monocytes CD14+CD16+ may contribute to immunopathology of the lungs, even death after an infection of SARS-CoV-2. A retrospective research review of 21 patients [23–28]was then performed by their team. Symptoms like fever and toxicity were greatly increased in a few days after the administration of tocilizumab. 75.0% (15/20) of patients got less oxygen after 5 days of treatment and 1 patient was not needed to be treated for oxygen. CT scans demonstrated the absorption of shadow in 19 cases of lung injury (90.5 percent). Peripheral blood lymphocytes returned steadily to normal. Favipiravir was a modern antiviral medication with broad range intended for the treatment of influenza, targeted RNA-dependent RNA polymerases (RdRp). The Chinese FDA (batch number: 2020L00005) approved favipiravir tablets for COVID-20 on 13 February 2020. Favipiravir has been shown to effectively prevent SARS-CoV-2-induced infection in Vero E6 cells (ATCC-1586). Coronavirus 2019 (Covid-19) is a serious acute pandemic of coronavirus 2 respiratory syndrome (SARS-CoV-2) disease (Guan et al., 2020). The disorder is often characterised by air signs which involves a wide variety of extreme conditions. Cytokine release Syndrome, an aberrant immune system host that may intensify lung damage and produce multiple organ dysfunctions, is formed in a subgroup of COVID-19 patients. Neurological cases of COVID-19, including a continuum of encephalitis with various underlying pathogenic pathways, are increasingly documented. SARS-CoV-2 can also induce virus encephalitis, secondary to the invasion of CNS, and especially a form of encephalopathy that appears to be connected to cytokine mediated neuroinflammation, among well-known entities such as acute disseminated encephalomyelitis, limbic encephalitis and acute necrotizing encephalopathy. This has not been specifically phenotyped to date, although it tends to be characterised by a modified mental state that vary from slight depression and delirium, linguistic [29–32] disorders and an acinetic mutism. Tocilizumab, an anti-interleukin (IL)-6 receptor antibody, has shown efficacy in the treatment of CRS systems with COVID-19, but remains uncertain about its role in the control of related CNS manifestations. Although COVID-19 underlies a very flexible pathophysiology, previous studies have shown that the concentrations of proinflammable cytokines, such as interleukin (IL)-6, IL-10, granulocylon stimulant factor, and tumour necrosis factor were higher in criically ill patients. The study of postmortem lung tissue histopathology showed that alveolar edoema, protein exude, inflammatory cellular invasion and microthrombosis had varying degrees. Other cofactors, such as dysregulation of host immune response and hyperinflammation could lead not only to the identified function

of associated serious thromboembolic disease (COVID-19) but also to the growth of lung and subsequent fibrosis. However, for reasons that remain unclear, only a subgroup of patients with COVID-19 experience genius respiratory failure. An constant problem is the optimal control of these situations. However, elevated amounts of other routine laboratory parameters, including C-RP, lactate dehydrogenase, and ferritin, D-dimer along with lymphocytopenia, were reported in COVID-19 cases of rapidly growing respiratory disease. IL-6 is a key inflammatory mediator when developing COVID-19 related hyperinflammation. A recombinant humanised monoclonal antibody, Tocilizumab (TCZ), was proposed to alleviate the related cytokine hurricane, COVID-19 for the treatment of extreme COVID-19, but with differing clinical outcomes, against both soluble and membrane-bound IL-6 receptors. We will present the clinical characteristics of COVID-19 patients who have undergone therapy with TCZ in this one-center retrospective review, and explain their course and outcomes.

REFERENCES:

1. Widysanto A, Kurniawan A, Lugito NPH, et al. Experience of using tocilizumab for treatment in Indonesian patients with severe COVID-19. *Cytokine*. 2021;138. doi:10.1016/j.cyto.2020.155393

2. Corominas H, Castellví I, Pomar V, et al. Effectiveness and safety of intravenous tocilizumab to treat COVID-19-associated hyperinflammatory syndrome: Covizumab-6 observational cohort. *Clin Immunol*. 2021;223. doi:10.1016/j.clim.2020.108631

3. Sabbatinelli J, Giuliani A, Matacchione G, et al. Decreased serum levels of the inflammaging marker miR-146a are associated with non-clinical response to tocilizumab in COVID-19 patients. *Mech Ageing Dev*. 2021;193. doi:10.1016/j.mad.2020.111413

4. Zhao H, Zhu Q, Zhang C, et al. Tocilizumab combined with favipiravir in the treatment of COVID-19: A multicenter trial in a small sample size. *Biomed Pharmacother*. 2021;133. doi:10.1016/j.biopha.2020.110825

5. Muccioli L, Pensato U, Cani I, et al. COVID-19-related encephalopathy presenting with aphasia resolving following tocilizumab treatment. *J Neuroimmunol*. 2020;349. doi:10.1016/j.jneuroim.2020.577400

6. Huang E, Jordan SC. Tocilizumab for Covid-19 - The ongoing search for effective therapies. *N Engl J Med*. 2020;383(24):2387-2388. doi:10.1056/NEJMe2032071

7. Stone JH, Frigault MJ, Serling-Boyd NJ, et al. Efficacy of tocilizumab in patients hospitalized with covid-19. *N Engl J Med*. 2020;383(24):2333-2344. doi:10.1056/NEJMoa2028836

8. Wang Y, Mao Q, Zhou X. Does tocilizumab have a magical therapeutic effect on COVID-19 patients without obvious adverse reactions? *Proc Natl Acad Sci U S A*. 2020;117(49):30896-30897. doi:10.1073/pnas.2009961117

9. Vu CA, DeRonde KJ, Vega AD, et al. Effects of Tocilizumab in COVID-19 patients: a cohort study. *BMC Infect Dis*. 2020;20(1). doi:10.1186/s12879-020-05701-4

10. Xu X, Han M, Li T, et al. Tocilizumab treatment in COVID-19 patients needs the

assessment of the disease severity and timely intervention. *Proc Natl Acad Sci U S A*. 2020;117(48):30027-30028. doi:10.1073/pnas.2011616117

11. Yang C, Liu E, Liu M. Safety concerns regarding concomitant use of tocilizumab and glucocorticoids in COVID-19 patients. *Proc Natl Acad Sci U S A*. 2020;117(48):30025-30026. doi:10.1073/pnas.2009253117

12. Salvati L, Occhipinti M, Gori L, et al. Pulmonary vascular improvement in severe COVID-19 patients treated with tocilizumab. *Immunol Lett*. 2020;228:122-128. doi:10.1016/j.imlet.2020.10.009

13. Rubio-Rivas M, Ronda M, Padulles A, et al. Beneficial effect of corticosteroids in preventing mortality in patients receiving tocilizumab to treat severe COVID-19 illness. *Int J Infect Dis*. 2020;101:290-297. doi:10.1016/j.ijid.2020.09.1486

14. de Cáceres C, Martínez R, Bachiller P, Marín L, García JM. The effect of tocilizumab on cytokine release syndrome in COVID-19 patients. *Pharmacol Reports*. 2020;72(6):1529-1537. doi:10.1007/s43440-020-00186-z

15. Tsai A, Diawara O, Nahass RG, Brunetti L. Impact of tocilizumab administration on mortality in severe COVID-19. *Sci Rep*. 2020;10(1). doi:10.1038/s41598-020-76187-y

16. Kaminski MA, Sunny S, Balabayova K, et al. Tocilizumab therapy for COVID-19: A comparison of subcutaneous and intravenous therapies. *Int J Infect Dis*. 2020;101:59-64. doi:10.1016/j.ijid.2020.09.1447

17. Malekzadeh R, Abedini A, Mohsenpour B, et al. Subcutaneous tocilizumab in adults with severe and critical COVID-19: A prospective open-label uncontrolled multicenter trial. *Int Immunopharmacol*. 2020;89. doi:10.1016/j.intimp.2020.107102

18. Tholin B, Hauge MT, Aukrust P, Fehrle L, Tvedt TH. Hemophagocytic lymphohistiocytosis in a patient with COVID-19 treated with tocilizumab: a case report. *J Med Case Rep*. 2020;14(1). doi:10.1186/s13256-020-02503-9

19. Samaee H, Mohsenzadegan M, Ala S, Maroufi SS, Moradimajd P. Tocilizumab for treatment patients with COVID-19: Recommended medication for novel disease. *Int Immunopharmacol*. 2020;89. doi:10.1016/j.intimp.2020.107018

20. Guaraldi G, Milic J, Cozzi-Lepri A, Pea F, Mussini C. Tocilizumab in COVID-19: finding the optimal route and dose – Authors' reply. *Lancet Rheumatol*. 2020;2(12):e739-e740. doi:10.1016/S2665-9913(20)30333-7

21. Jain S, Jain S, Sharma SK. Tocilizumab in COVID-19: finding the optimal route and dose. *Lancet Rheumatol*. 2020;2(12):e738-e739. doi:10.1016/S2665-9913(20)30334-9

22. Bernardo L, Del Sesto S, Giordano L, et al. Severe prolonged neutropenia following administration of tocilizumab in a patient affected by COVID-19: a case report and brief review of the literature. *Drugs Ther Perspect*. 2020;36(12):568-572. doi:10.1007/s40267-020-00777-z

23. Mantero V, Rigamonti A, Basilico P, Crespi M, Balgera R, Salmaggi A. Mild COVID-19 infection in an NMO patient treated with tocilizumab: a confirmation of anti-IL-6 protective role? *J Neurol*. 2020;267(12):3465-3466. doi:10.1007/s00415-020-10039-7

24. Wise J. Covid-19: Critically ill patients treated with arthritis drug tocilizumab show improved outcomes, researchers report. *BMJ*. 2020;371:m4530.

doi:10.1136/bmj.m4530

25. Nakamura H, Miyagi K, Otsuki M, et al. Acute hypertriglyceridaemia caused by tocilizumab in a patient with severe COVID-19. *Intern Med*. 2020;59(22):2945-2949. doi:10.2169/internalmedicine.5244-20

26. Jiménez-Brítez G, Ruiz P, Soler X. Tocilizumab plus glucocorticoids in severe and critically COVID-19 patients. A single center experience [Tocilizumab más glucocorticoides para tratar pacientes graves y en situación crítica infectados por COVID-19. Experiencia de un centro]. *Med Clin (Barc)*. 2020;155(9):410-411. doi:10.1016/j.medcli.2020.07.001

27. Kaye AG, Siegel R. The efficacy of IL-6 inhibitor Tocilizumab in reducing severe COVID-19 mortality: a systematic review. *PeerJ*. 2020;8. doi:10.7717/peerj.10322

28. Berardicurti O, Ruscitti P, Ursini F, et al. Mortality in tocilizumab-treated patients with COVID-19: a systematic review and meta-analysis. *Clin Exp Rheumatol*. 2020;38(6):1247-1254. https://www.scopus.com/inward/record.uri?eid=2-s2.0-85097310697&partnerID=40&md5=d8fecf71b30d28052df7f9427f1e07a7.

29. Gergi M, Cushman M, Littenberg B, Budd RC. Thromboinflammation response to tocilizumab in COVID-19. *Res Pract Thromb Haemost*. 2020;4(8):1262-1268. doi:10.1002/rth2.12436

30. Guisado-Vasco P, Valderas-Ortega S, Carralón-González MM, et al. Clinical characteristics and outcomes among hospitalized adults with severe COVID-19 admitted to a tertiary medical center and receiving antiviral, antimalarials, glucocorticoids, or immunomodulation with tocilizumab or cyclosporine: A retrospective observational study (COQUIMA cohort). *EClinicalMedicine*. 2020;28. doi:10.1016/j.eclinm.2020.100591

31. Algazaq J, Hiraldo-Infante C, Miskovsky J. Tocilizumab treatment in COVID-19-induced cytokine release syndrome. *Infect Dis Clin Pract*. 2020;28(6):e76-e78. doi:10.1097/IPC.0000000000000940

32. Naqvi M, Zakowski P, Glucksman L, Smithson S, Burwick RM. Tocilizumab and Remdesivir in a Pregnant Patient With Coronavirus Disease 2019 (COVID-19). *Obstet Gynecol*. 2020;136(5):1025-1029. doi:10.1097/AOG.0000000000004050